Does the media refer more to ZVRA or NERV?

In the previous week, Minerva Neurosciences had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 2 mentions for Minerva Neurosciences and 1 mentions for Zevra Therapeutics. Minerva Neurosciences' average media sentiment score of 0.55 beat Zevra Therapeutics' score of 0.42 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRMD or NERV?

In the previous week, Minerva Neurosciences had 1 more articles in the media than CorMedix. MarketBeat recorded 2 mentions for Minerva Neurosciences and 1 mentions for CorMedix. CorMedix's average media sentiment score of 0.82 beat Minerva Neurosciences' score of 0.55 indicating that CorMedix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PHAT or NERV more profitable?

Minerva Neurosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%. Company Net Margins Return on Equity Return on Assets Phathom Pharmaceuticals -41.34% N/A -20.81% Minerva Neurosciences N/A N/A -31.72%

Does the media prefer PHAT or NERV?

In the previous week, Phathom Pharmaceuticals had 6 more articles in the media than Minerva Neurosciences. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.55 beat Phathom Pharmaceuticals' score of 0.52 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NERV or AQST more profitable?

Minerva Neurosciences has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -31.72% Aquestive Therapeutics -144.63% N/A -52.40%

Does the media prefer NERV or AQST?

In the previous week, Aquestive Therapeutics had 4 more articles in the media than Minerva Neurosciences. MarketBeat recorded 6 mentions for Aquestive Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.55 beat Aquestive Therapeutics' score of 0.51 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aquestive Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor NERV or OCS?

In the previous week, Oculis had 9 more articles in the media than Minerva Neurosciences. MarketBeat recorded 11 mentions for Oculis and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.55 beat Oculis' score of 0.12 indicating that Minerva Neurosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Minerva Neurosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oculis 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 2 Very Negative mention(s) Neutral

Minerva Neurosciences (NERV) Competitors

$3.28 +0.05 (+1.55%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$3.27 -0.01 (-0.30%)

As of 10/2/2026 07:30 PM Eastern

Compare

NERV vs. ZVRA, CRMD, PHAT, AQST, and OCS

Should you buy Minerva Neurosciences stock or one of its competitors? Minerva Neurosciences's main competitors and comparable companies include Zevra Therapeutics (ZVRA), CorMedix (CRMD), Phathom Pharmaceuticals (PHAT), Aquestive Therapeutics (AQST), and Oculis (OCS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Minerva Neurosciences compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

Zevra Therapeutics has a beta of 0.98, meaning that its share price is 2% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

In the previous week, Minerva Neurosciences had 1 more articles in the media than Zevra Therapeutics. MarketBeat recorded 2 mentions for Minerva Neurosciences and 1 mentions for Zevra Therapeutics. Minerva Neurosciences' average media sentiment score of 0.55 beat Zevra Therapeutics' score of 0.42 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Zevra Therapeutics currently has a consensus price target of $27.14, indicating a potential upside of 171.70%. Minerva Neurosciences has a consensus price target of $10.33, indicating a potential upside of 215.04%. Given Minerva Neurosciences' higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	3.00
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Zevra Therapeutics has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	5.57	$83.23M	$0.92	10.86
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

Zevra Therapeutics has a net margin of 42.82% compared to Minerva Neurosciences' net margin of 0.00%. Zevra Therapeutics' return on equity of 54.54% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Minerva Neurosciences	N/A	N/A	-31.72%

Summary

Zevra Therapeutics beats Minerva Neurosciences on 13 of the 16 factors compared between the two stocks.

How does Minerva Neurosciences compare to CorMedix?

CorMedix (NASDAQ:CRMD) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.

CorMedix has higher revenue and earnings than Minerva Neurosciences. Minerva Neurosciences is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$311.71M	1.80	$163.05M	$2.14	3.36
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

CorMedix currently has a consensus price target of $15.00, suggesting a potential upside of 108.62%. Minerva Neurosciences has a consensus price target of $10.33, suggesting a potential upside of 215.04%. Given Minerva Neurosciences' higher possible upside, analysts clearly believe Minerva Neurosciences is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

In the previous week, Minerva Neurosciences had 1 more articles in the media than CorMedix. MarketBeat recorded 2 mentions for Minerva Neurosciences and 1 mentions for CorMedix. CorMedix's average media sentiment score of 0.82 beat Minerva Neurosciences' score of 0.55 indicating that CorMedix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CorMedix	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

34.2% of CorMedix shares are held by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are held by institutional investors. 3.5% of CorMedix shares are held by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

CorMedix has a net margin of 40.49% compared to Minerva Neurosciences' net margin of 0.00%. CorMedix's return on equity of 40.52% beat Minerva Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Minerva Neurosciences	N/A	N/A	-31.72%

CorMedix has a beta of 1.4, suggesting that its stock price is 40% more volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market.

Summary

CorMedix beats Minerva Neurosciences on 12 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Phathom Pharmaceuticals has higher revenue and earnings than Minerva Neurosciences. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	3.20	-$221.25M	-$1.28	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A

99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 9.3% of Phathom Pharmaceuticals shares are owned by insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Phathom Pharmaceuticals presently has a consensus price target of $21.25, suggesting a potential upside of 207.08%. Minerva Neurosciences has a consensus price target of $10.33, suggesting a potential upside of 215.04%. Given Minerva Neurosciences' higher possible upside, analysts plainly believe Minerva Neurosciences is more favorable than Phathom Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Minerva Neurosciences has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -41.34%.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-41.34%	N/A	-20.81%
Minerva Neurosciences	N/A	N/A	-31.72%

In the previous week, Phathom Pharmaceuticals had 6 more articles in the media than Minerva Neurosciences. MarketBeat recorded 8 mentions for Phathom Pharmaceuticals and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.55 beat Phathom Pharmaceuticals' score of 0.52 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Phathom Pharmaceuticals has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.1, meaning that its share price is 110% less volatile than the broader market.

Summary

Phathom Pharmaceuticals beats Minerva Neurosciences on 11 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Aquestive Therapeutics?

Minerva Neurosciences (NASDAQ:NERV) and Aquestive Therapeutics (NASDAQ:AQST) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 32.5% of Aquestive Therapeutics shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Comparatively, 6.8% of Aquestive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Minerva Neurosciences currently has a consensus target price of $10.33, indicating a potential upside of 215.04%. Aquestive Therapeutics has a consensus target price of $9.17, indicating a potential upside of 101.47%. Given Minerva Neurosciences' higher probable upside, equities analysts plainly believe Minerva Neurosciences is more favorable than Aquestive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Aquestive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Aquestive Therapeutics has higher revenue and earnings than Minerva Neurosciences. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Aquestive Therapeutics	$54.09M	10.56	-$83.78M	-$0.65	N/A

Minerva Neurosciences has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market. Comparatively, Aquestive Therapeutics has a beta of 1.49, suggesting that its share price is 49% more volatile than the broader market.

Minerva Neurosciences has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -144.63%.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Aquestive Therapeutics	-144.63%	N/A	-52.40%

In the previous week, Aquestive Therapeutics had 4 more articles in the media than Minerva Neurosciences. MarketBeat recorded 6 mentions for Aquestive Therapeutics and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.55 beat Aquestive Therapeutics' score of 0.51 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aquestive Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Aquestive Therapeutics beats Minerva Neurosciences on 9 of the 15 factors compared between the two stocks.

How does Minerva Neurosciences compare to Oculis?

Minerva Neurosciences (NASDAQ:NERV) and Oculis (NASDAQ:OCS) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

Minerva Neurosciences has a beta of -0.1, suggesting that its share price is 110% less volatile than the broader market. Comparatively, Oculis has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

Oculis has higher revenue and earnings than Minerva Neurosciences. Oculis is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$28.87	N/A
Oculis	$1.45M	349.08	-$119.44M	-$1.74	N/A

34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 22.3% of Oculis shares are held by institutional investors. 1.7% of Minerva Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Oculis had 9 more articles in the media than Minerva Neurosciences. MarketBeat recorded 11 mentions for Oculis and 2 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 0.55 beat Oculis' score of 0.12 indicating that Minerva Neurosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Minerva Neurosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oculis	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Minerva Neurosciences has a net margin of 0.00% compared to Oculis' net margin of -6,777.18%. Minerva Neurosciences' return on equity of 0.00% beat Oculis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-31.72%
Oculis	-6,777.18%	-42.61%	-35.23%

Minerva Neurosciences presently has a consensus target price of $10.33, indicating a potential upside of 215.04%. Oculis has a consensus target price of $39.44, indicating a potential upside of 351.83%. Given Oculis' stronger consensus rating and higher probable upside, analysts plainly believe Oculis is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
Oculis	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Oculis beats Minerva Neurosciences on 8 of the 15 factors compared between the two stocks.

Get Minerva Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NERV vs. The Competition

Export

Metric	Minerva Neurosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$154.23M	$12.27B	$7.13B	$13.14B
Dividend Yield	N/A	2.64%	2.53%	16.77%
P/E Ratio	-0.11	794.62	273.77	26.04
Price / Sales	N/A	839.20	614.30	85.58
Price / Cash	N/A	82.26	77.60	51.75
Price / Book	-1.01	10.46	10.92	6.30
Net Income	-$293.42M	$2.83B	$3.50B	$361.43M
7 Day Performance	-3.53%	-1.56%	-2.07%	-1.67%
1 Month Performance	-30.06%	-5.67%	-6.21%	-4.51%
1 Year Performance	54.79%	-4.72%	7.45%	2.03%

Minerva Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NERV Minerva Neurosciences	1.5131 of 5 stars	$3.28 +1.5%	$10.33 +215.0%	+57.6%	$154.23M	N/A	N/A	7	News Coverage Positive News
ZVRA Zevra Therapeutics	4.5028 of 5 stars	$11.58 -0.8%	$27.14 +134.4%	+7.3%	$693.01M	$106.47M	12.59	61
CRMD CorMedix	2.7827 of 5 stars	$7.78 +0.1%	$15.00 +92.8%	-34.9%	$605.63M	$311.71M	3.64	191	News Coverage Positive News
PHAT Phathom Pharmaceuticals	3.4173 of 5 stars	$7.76 +4.2%	$21.25 +173.8%	-41.5%	$602.71M	$175.11M	N/A	371
AQST Aquestive Therapeutics	1.9185 of 5 stars	$4.95 +3.6%	$9.17 +85.2%	-21.1%	$599.95M	$44.54M	N/A	147	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NERV) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Minerva Neurosciences (NERV) Competitors

NERV vs. ZVRA, CRMD, PHAT, AQST, and OCS

How does Minerva Neurosciences compare to Zevra Therapeutics?

Summary

How does Minerva Neurosciences compare to CorMedix?

Summary

How does Minerva Neurosciences compare to Phathom Pharmaceuticals?

Summary

How does Minerva Neurosciences compare to Aquestive Therapeutics?

Summary

How does Minerva Neurosciences compare to Oculis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Minerva Neurosciences (NERV) Competitors

NERV vs. ZVRA, CRMD, PHAT, AQST, and OCS

How does Minerva Neurosciences compare to Zevra Therapeutics?

Which has more volatility and risk, ZVRA or NERV?

Does the media refer more to ZVRA or NERV?

Do insiders & institutionals hold more shares of ZVRA or NERV?

Do analysts prefer ZVRA or NERV?

Which has stronger valuation and earnings, ZVRA or NERV?

Is ZVRA or NERV more profitable?

Summary

How does Minerva Neurosciences compare to CorMedix?

Which has stronger earnings and valuation, CRMD or NERV?

Do analysts prefer CRMD or NERV?

Does the media favor CRMD or NERV?

Do insiders & institutionals hold more shares of CRMD or NERV?

Is CRMD or NERV more profitable?

Which has more volatility & risk, CRMD or NERV?

Summary

How does Minerva Neurosciences compare to Phathom Pharmaceuticals?

Which has stronger earnings and valuation, PHAT or NERV?

Do institutionals & insiders hold more shares of PHAT or NERV?

Do analysts rate PHAT or NERV?

Is PHAT or NERV more profitable?

Does the media prefer PHAT or NERV?

Which has more volatility and risk, PHAT or NERV?

Summary

How does Minerva Neurosciences compare to Aquestive Therapeutics?

Do insiders and institutionals have more ownership in NERV or AQST?

Do analysts rate NERV or AQST?

Which has preferable valuation & earnings, NERV or AQST?

Which has more risk and volatility, NERV or AQST?

Is NERV or AQST more profitable?

Does the media prefer NERV or AQST?

Summary

How does Minerva Neurosciences compare to Oculis?

Which has more volatility and risk, NERV or OCS?

Which has preferable valuation and earnings, NERV or OCS?

Do insiders & institutionals believe in NERV or OCS?

Does the media favor NERV or OCS?

Is NERV or OCS more profitable?

Do analysts recommend NERV or OCS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NERV vs. The Competition

Minerva Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools